Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, ...

Prostate cancer is one of the top diagnoses for men with cancer, but early stages are tough to detect.

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in ...

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research ...

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...

Here’s the state of prostate cancer, according to a new Lancet Commission on Prostate Cancer report just published on April 4 in The Lancet. It’s already the most common cancer among men in 112 ...

Approximately one in eight American men will be diagnosed with prostate cancer during their lifetime. For most of them, if ...

A new study has highlighted a significant knowledge gap among patients about repeat radiotherapy (reirradiation) as a treatment option for recurrent prostate cancer ...

A new podcast fronted by writer, comedian and broadcaster Jon Holmes is aiming to help men better understand their prostate cancer treatment options ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...